Welcome to our dedicated page for Alimera Sciences news (Ticker: ALIM), a resource for investors and traders seeking the latest updates and insights on Alimera Sciences stock.
Alimera Sciences, Inc. (NASDAQ: ALIM) is a leading global pharmaceutical company committed to advancing retinal health. Founded in June 2003, the company specializes in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. Alimera's primary focus is on diseases affecting the retina, particularly those that are not well managed by current therapies. The company's flagship product, ILUVIEN, is a sustained-release intravitreal implant used for the treatment of diabetic macular edema (DME) and non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) outside the U.S.
ILUVIEN utilizes CONTINUOUS MICRODOSING™ technology, releasing sub-microgram levels of fluocinolone acetonide, a corticosteroid, for up to 36 months. This technology helps to reduce disease recurrence, thereby enabling patients to maintain vision longer with fewer injections. ILUVIEN is approved in the U.S. and multiple international markets, including 17 European countries, China, and regions in the Middle East.
Recently, Alimera announced positive data from several clinical studies, such as the PALADIN study, which evaluated the long-term safety of ILUVIEN in treating DME. The company also made headlines by completing enrollment for the Synchronicity Study, focusing on YUTIQ, another fluocinolone acetonide intravitreal implant for chronic non-infectious uveitis.
Moreover, Alimera continues to expand its executive team to strengthen its financial and operational capabilities. Elliot Maltz, C.P.A., has been named as the new Chief Financial Officer to drive growth and improve cash flow. The company's European operations are managed through its subsidiary, Alimera Sciences Limited, based in London.
Financially, Alimera Sciences has shown robust growth. In Q4 2023, the company reported net revenues of $26.3 million, an 88% increase compared to the same period in 2022. For the full year 2023, net revenues were up 49% to $80.8 million. This growth is a testament to the successful commercialization of ILUVIEN and YUTIQ.
Looking ahead, Alimera aims to further its mission of being invaluable to patients, physicians, and partners concerned with retinal health. The company is actively involved in numerous clinical studies and regulatory efforts to expand the therapeutic indications for its products, ensuring continued innovation and improved patient outcomes.
For more information, please visit www.alimerasciences.com.
Alimera Sciences (Nasdaq: ALIM) reports preliminary consolidated net revenue exceeding $13.5 million for Q4 2020, contributing to over $50.5 million for the entire year. The company ended the year with $11.2 million in cash. Despite challenges posed by COVID-19, Alimera anticipates a recovery and expects fourth-quarter sales to surpass those from Q3 2020. The company highlights the potential increased adoption of its product, ILUVIEN, owing to its long-acting benefits during the pandemic. Detailed results will be discussed in an upcoming earnings call.
Alimera Sciences (Nasdaq: ALIM), a leader in ophthalmology treatments, announces that President and CEO Rick Eiswirth will present at the H.C. Wainwright Bioconnect 2021 Virtual Conference from January 11-14, 2021. The presentation will be available for on-demand listening from 6:00 AM ET on January 11 until the end of business on January 14, 2021. Registration for the presentation can be accessed online. Alimera focuses on developing treatments for retinal diseases, addressing unmet needs in an aging population.
Alimera Sciences has launched ILUVIEN in the Netherlands, targeting diabetic macular edema (DME) and non-infectious posterior uveitis (NIPU). This launch, in collaboration with distribution partner Horus Pharma, marks a significant step in Alimera's geographic expansion strategy. ILUVIEN, a sustained release intravitreal implant, is anticipated to improve patient outcomes with its CONTINUOUS MICRODOSING technology, allowing for longer intervals between treatments. The product has received high levels of interest from local ophthalmologists and patients, with some injections already scheduled.
Alimera Sciences (Nasdaq: ALIM) will present a corporate overview at the LD Micro Main Event virtual investor conference on December 14 at 8:20 AM PST/11:20 AM EST. CEO Rick Eiswirth's presentation will include a 10-minute overview followed by a Q&A session. Interested participants can register to attend the presentation at ve.mysequire.com. Alimera focuses on the commercialization and development of prescription ophthalmic treatments for retinal diseases, addressing significant unmet needs in this therapeutic area.
Alimera Sciences (NASDAQ: ALIM) has announced that its President and CEO, Rick Eiswirth, will participate in the Craig-Hallum Capital Group’s annual Alpha Select Conference on November 17, 2020. This event will focus on one-on-one and small group meetings conducted via video conference. Alimera specializes in prescription ophthalmic treatments aimed at retinal diseases, addressing significant needs in an aging population where current therapies are lacking. For more information, visit www.alimerasciences.com.
On November 12, 2020, Alimera Sciences (NASDAQ: ALIM) announced the presentation of new real-world clinical data for ILUVIEN at the American Academy of Ophthalmology 2020 Virtual Conference, starting November 13. The data highlights outcomes from the IDEAL and IRISS registry studies, showcasing ILUVIEN's effectiveness in reducing the recurrence of diabetic macular edema. ILUVIEN is a sustained-release implant providing long-term benefits with fewer injections, enhancing patient outcomes in managing retinal diseases.
Alimera Sciences reported a consolidated net revenue of $12.5 million for Q3 2020, a 25% increase from Q2 2020 but a 3% decline from Q3 2019. U.S. net revenue reached $7.0 million, reflecting a 20% decrease from the previous year but a 106% rise sequentially. The net loss reduced to $(0.6 million) from $(3.1 million) in Q3 2019, and adjusted EBITDA was positive at $1.4 million. Despite challenges, international revenue grew 31% year-over-year, driven by direct sales efforts. Management also initiated the NEW DAY clinical trial.
Alimera Sciences (Nasdaq: ALIM) will report its third quarter 2020 financial results on October 28, 2020, after the market closes. A conference call will be held on October 29, 2020, at 9:00 AM ET to discuss these results and provide updates on corporate developments. Participants can pre-register for the call, and it will also be available via a live webcast. The call's replay will be accessible for a limited time.
Alimera specializes in the development of prescription ophthalmic pharmaceuticals focusing on retinal diseases.
Alimera Sciences (Nasdaq: ALIM) announced that clinical data for ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19mg will be presented in over 20 papers at the EURETINA 2020 Virtual Congress, scheduled for October 2-4, 2020. Key findings support ILUVIEN's safety and efficacy as a three-year treatment system for diabetic macular edema (DME) and non-infectious uveitis. Significant papers include long-term observational data from various clinics, showcasing ILUVIEN's potential in managing retinal diseases.
Alimera Sciences (NASDAQ: ALIM) announced that CEO Rick Eiswirth will present a corporate overview at the H. C. Wainwright and Company 22nd Annual Global Virtual Investor Conference on September 15, 2020, at 3:30 PM ET. Interested parties can listen live via an online sign-up. An archived presentation will be available on Alimera's website starting September 16. Additionally, Eiswirth will conduct virtual one-on-one meetings from September 14-16, 2020, with scheduling available through conference coordinators.
FAQ
What is the current stock price of Alimera Sciences (ALIM)?
What is the market cap of Alimera Sciences (ALIM)?
What is Alimera Sciences, Inc. specialized in?
What is ILUVIEN?
Where is Alimera Sciences headquartered?
What are the latest financial results for Alimera Sciences?
Who is the new Chief Financial Officer of Alimera Sciences?
What recent clinical studies has Alimera Sciences completed?
In which regions is ILUVIEN approved?
What is the mission of Alimera Sciences?
What technology does ILUVIEN utilize?
Where can I find more information about Alimera Sciences?
